Preclinical characterization of ARRY-575: a potent, selective, and orally bio-available small molecule inhibitor of Chk1

被引：0
|
作者：
Humphries, M. J. [1 ]
von Carlowitz, I. [1 ]
Le Huerou, Y. L. [1 ]
Randolph, N. [1 ]
Gunawardana, I. [1 ]
Mohr, P. J. [1 ]
Wang, B. [1 ]
Lyon, M. A. [1 ]
Chicarelli, M. [1 ]
Sullivan, F. [1 ]
Blake, J. F. [1 ]
Winski, S. L. [1 ]
Wallace, E. [1 ]
机构：
[1] Array BioPharma, Boulder, CO USA
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    Constance King
    Henry Diaz
    Darlene Barnard
    David Barda
    David Clawson
    Wayne Blosser
    Karen Cox
    Sherry Guo
    Mark Marshall
    Investigational New Drugs, 2014, 32 : 213 - 226
  • [2] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    King, Constance
    Diaz, Henry
    Barnard, Darlene
    Barda, David
    Clawson, David
    Blosser, Wayne
    Cox, Karen
    Guo, Sherry
    Marshall, Mark
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 213 - 226
  • [3] Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials
    Marshall, Mark
    Barda, David
    Barnard, Darlene
    Cox, Karen
    Diaz, H. Bruce
    King, Constance
    Nutter, Suzanne
    Westin, Eric
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [4] Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1.
    Bhagwat, Neha
    Grego, Alexander
    Gowen-MacDonald, William
    Wang, Min
    Cowart, Miles
    Wu, Xiaowei
    Zhuo, Jincong
    Combs, Andrew
    Ruggeri, Bruce
    Scherle, Peggy
    Vaddi, Kris
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Targeting the replication checkpoint with a potent and selective CHK1 inhibitor
    Parry, David
    Shanahan, Frances
    Davis, Nicole
    Wiswell, Derek
    Seghezzi, Wolfgang
    Pierce, Robert
    Hsieh, Yunsheng
    Paruch, Kamil
    Guzi, Timothy
    CANCER RESEARCH, 2009, 69
  • [6] Preclinical development of a selective, potent small molecule ALK inhibitor
    Lovly, Christine M.
    de Stanchina, Elisa
    Liang, Chris
    Pao, William
    CANCER RESEARCH, 2010, 70
  • [7] Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
    Leviten, Dina
    Sierra, Teresa
    Dozier, Ashley
    Boyce, Richard
    Boyle, Bob
    Peterson, Scott
    Vo, Alex C.
    CANCER RESEARCH, 2017, 77
  • [8] Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction
    Ki, Dong Hyuk
    Yu, Hana
    Kim, Donggeon
    Jeon, Yeejin
    Jo, Seongin
    Nam, Joonwoo
    Kim, Eun-Jung
    Kim, Sungeun
    Choi, Hunmi
    Kim, Jieun
    Yu, Jihyun
    Choi, Sungpil
    Han, Wooseok
    CANCER RESEARCH, 2024, 84 (06)
  • [9] A potent, selective and orally bioavailable small molecule inhibitor of MCL1 for the treatment of cancer
    Matson, Clinton K.
    Kenney, Thomas
    Steiner, Bart H.
    Deodato, Chloe R.
    Yahiaoui, Anella
    Rubio, Claudia A.
    Chan, Julie T.
    Mollova, Nevena
    Keegan, Kathleen S.
    Venkataramani, Chandrasekar
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor
    Marshall, M.
    King, C.
    Barnard, D.
    Diaz, H.
    Barda, D.
    Bence, A.
    Westin, E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 65 - 65
12345